PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics
Authors
Keywords
-
Journal
SEMINARS IN ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-10-14
DOI
10.1053/j.seminoncol.2023.09.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
- (2022) A. Poveda et al. GYNECOLOGIC ONCOLOGY
- Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment
- (2022) Cen Guo et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors
- (2021) Chandrasekar Durairaj et al. CLINICAL PHARMACOKINETICS
- The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study
- (2021) Song Mu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
- (2021) Fred Saad et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
- (2021) Nikolay Grechko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Population Pharmacokinetic Meta‐analysis of Veliparib, a PARP Inhibitor, Across Phase I/II/III Trials in Cancer Patients
- (2021) Sven Stodtmann et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Human Mass Balance and Metabolite Profiling of [ 14 C]‐Pamiparib, a Poly (ADP‐Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer
- (2021) Song Mu et al. Clinical Pharmacology in Drug Development
- A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
- (2021) Mingxiang Liao et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
- (2021) Mehmet Akce et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Fuzuloparib: First Approval
- (2021) Arnold Lee DRUGS
- Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor
- (2020) Mingxiang Liao et al. XENOBIOTICA
- Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
- (2020) Christian Rolfo et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment
- (2019) Christian Rolfo et al. CLINICAL PHARMACOKINETICS
- A Phase 1 Mass Balance Study of 14 C‐Labeled Talazoparib in Patients With Advanced Solid Tumors
- (2019) Yanke Yu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
- (2019) Mingxiang Liao et al. INVESTIGATIONAL NEW DRUGS
- Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumors
- (2019) Mohamed Elmeliegy et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
- (2017) Lotte van Andel et al. INVESTIGATIONAL NEW DRUGS
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies
- (2016) Luc Dirix et al. CLINICAL THERAPEUTICS
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
- (2016) J. Mateo et al. Targeted Oncology
- Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours
- (2015) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now